Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

Rhea-AI Summary

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q4 and the year ending December 31, 2021, on March 10, 2022, after market close. The company focuses on developing first-in-class restorative therapeutics, utilizing innovative technology that includes cell-conditioned media and extracellular matrix materials from hypoxia-induced multipotent cells. Histogen aims to provide solutions for various therapeutic applications, including joint cartilage regeneration and soft tissue repair.

Positive

• Potential first-in-class therapeutic development.
• Innovative technology platform targeting joint and soft tissue repair.

Negative

• None.

News Market Reaction – HSTO

-9.70%

-9.70% Session move

In the trading session that priced this news, HSTO declined 9.70%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President & CFO Histogen Inc.
ir@histogen.com

FAQ

When will Histogen Inc. release its Q4 2021 financial results?

Histogen Inc. will release its Q4 2021 financial results on March 10, 2022, after market close.

What therapeutic areas does Histogen focus on?

Histogen focuses on developing therapeutics for joint cartilage regeneration, spinal disk repair, and soft tissue repair.

What is the stock symbol for Histogen?

The stock symbol for Histogen is HSTO.

What is Histogen's approach to developing therapeutics?

Histogen's approach involves utilizing cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells.